In addition to historical facts, this Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Forward-looking statements include information concerning our possible or assumed future results of our business, financial condition, results of operations, liquidity, anticipated growth strategies, anticipated trends in our industry, market size, our potential growth opportunities, plans and objectives. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions that convey uncertainty of future events or outcomes and the negatives of those terms.
These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we expect, project, believe, anticipate, intend or project will or may occur in the future. The statements that we make regarding the following matters are forward-looking by their nature:
| ◾ | whether we or our subsidiaries are able to raise capital on commercially reasonable terms to sustain the financial condition of each respective entity; |
| ◾ | the extent to which we continue to maintain our holdings in our subsidiary companies; |
| ◾ | the extent to which our discoveries and product candidates will have the desired effect so as to reach the stage of commercialization; |
| ◾ | whether we are able to achieve commercialization of our product candidates; |
| ◾ | whether we and our collaborators are able to allocate the resources needed to develop commercial products from our discoveries and product candidates; |
| ◾ | the length and degree of complexity of the process of our developing commercial products based on our discoveries and product candidates and the probability of our success, and the success of our collaborators, in developing such products; |
| ◾ | whether we are able to efficiently produce and scale up the production of our products, whether ourselves or through third party contractors, to achieve our commercialization targets; |
| ◾ | the degree of success of third parties whom we rely on to conduct certain activities, such as field-trials and pre-clinical studies; |
| ◾ | whether we can mitigate risks associated with disruptions to our information technology and systems, including cybersecurity threats and reliance on cloud computing services; |
| ◾ | whether we can maintain and expand our collaboration agreements in a consolidating industry with limited major players; |
| ◾ | whether we and our subsidiaries are able to comply with applicable law and the associated regulatory requirements that currently apply or become applicable to each respective business; |
| ◾ | the extent of the future growth of the agriculture, human health and industrial application industries in which we operate; |
| ◾ | whether we can maintain our current business models; |
| ◾ | the actual commercial value of our key product candidates; |
| ◾ | whether we or our collaborators receive regulatory approvals for the product candidates developed by us or our collaborators; |
| ◾ | whether milestones are met by us or by our collaborators with respect to our product candidates that generate revenues and whether products containing or based on our discoveries are commercialized and generate revenues or royalties; |
| ◾ | whether we are able to recruit, retain and develop knowledgeable or specialized personnel to perform our research and development work; |
| ◾ | the degree of our success at adapting to the continuous technological changes in our industries; |
| ◾ | whether we can maintain our collaboration agreements with our current collaborators or enter into new collaboration agreements and expand our research and development to new fields; |
| ◾ | whether we can improve our existing, or develop and launch new, computational technologies and screening and validation systems; |
| ◾ | whether we can patent our discoveries and protect our trade secrets and proprietary know-how; |
| ◾ | whether we can mitigate risks associated with potential product liability, environmental hazards, and regulatory compliance in handling toxic materials; and |
| ◾ | conditions in Israel, including Israel’s conflicts with Hamas and other parties in the region, as well as political and economic instability. |
The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the risks described in “Item 3.D. Risk Factors” and the additional information contained in “Item 4. Information on the Company” and “Item 5. Operating and Financial Review and Prospects.”
